House Democrats are pushing for access to Jeffrey Epstein's 'birthday book,' which allegedly includes a controversial letter from Donald Trump. This move comes as Ghislaine Maxwell is set for deposition, raising questions about Epstein's ties to powerful figures.
Amid international outcry over a severe hunger crisis, Israel announces the opening of humanitarian corridors for aid to Gaza, with the first air drops of food supplies already underway. This move follows accusations of deliberate starvation.
As Texas Republicans push for early redistricting, governors nationwide are caught in a political showdown. Will Democrats retaliate with their own redistricting plans? Find out how this could impact the upcoming midterm elections.
OpenAI is gearing up to launch GPT-5, the next-generation AI model, as early as August. CEO Sam Altman hints at exciting new features and improved coding capabilities. Get ready for a revolutionary update in AI technology!
President Trump boasts of a $550 billion investment from Japan to boost the U.S. economy, but how much of it is real? Explore the details and implications of this major trade framework.
CBS has announced the cancellation of 'The Late Show with Stephen Colbert,' sparking debate about the future of late night television. As streaming services rise, traditional TV faces mounting pressures. What does this mean for shows like 'Jimmy Kimmel Live'?
A former CIA officer claims the White House and Tulsi Gabbard are misrepresenting Russia's role in the 2016 election. She insists the aim was to help Trump, not sabotage him. Discover the explosive details!
Marvel/Disney’s The Fantastic Four: First Steps has kicked off its international rollout with an impressive $27M in just two days, outperforming previous superhero films. With strong openings in key markets, the film is set to break records!
Dive into the mixed experiences of using Alexa+, Amazon's latest voice assistant. It's smarter and more conversational, but is it truly worth the upgrade? Find out the pros, cons, and everything in between.
The European Medicines Agency has recommended the approval of lenacapavir, a twice-yearly injectable drug that could revolutionize HIV prevention and significantly reduce transmission rates globally.
